Illumina, Inc. v. Illumina Healthcare, LLC et al, flsdc:1:2020cv21102

chemicals, namely reagents for scientific or medical research use for analyzing cells, proteins, nucleic acids and other molecules of 50 to 10,000 daltons, sequencing DNA, genotyping, gene expression profiling and high through-put screening;

scientific and medical research, namely, analysis of cells, proteins, nucleic acids and other molecules of 50 to 10,000 daltons, sequencing DNA, genotyping, gene expression profiling and high through-put screening;

Scientific equipment and instruments, namely scanners, hybridization stations and fluidics delivery and computer systems sold as a unit and cassettes containing molecular sensing optical fiber bundles for analyzing cells, proteins, nucleic acids and other molecules of 50 to 10,000 Dalton, sequencing DNA, genotype, gene expression profiling and high through-put screening;

Developing, to the order and specification of others, biological and/or chemical sensing systems which use random array technology to identify [ inorganic and ] organic molecules, compounds and substances;

Nucleic acid analysis services in the field of scientific, pharmaceutical and medical research;

Reagent kits composed primarily of oligonucleotides, enzymes and buffers for nucleic acid detection in the fields of scientific, pharmaceutical and medical research;

Reagent kits composed primarily of oligonucleotides, enzymes and buffers for nucleic acid detection in the fields of scientific, pharmaceutical and medical research;

[ Nucleic acid analysis services in the fields of scientific, pharmaceutical and medical research ];